Because the molecular clock in the melatonin-producing cells of the pineal gland plays a key role in modulating circadian behavior [110], since circadian clocks are considered potential therapeutic targets to attenuate onsets and progressions of neurodegenerative diseases like AD [94], and considering melatonin therapy as an advantageous modality in terms of therapeutics [111], using melatonin-based approaches to mitigate circadian rhythm disruptions in aging and neurodegenerative diseases would certainly delay the onset or abate the development of AD pathogenesis. The gene discussed is CLOCK; the disease is neurodegenerative disease.